Exosens Shareholder HLD Europe Sells 9.8% Stake In Company to Theon International

HLD Europe, a shareholder in the French medical technology company Exosens SAS, has sold a 9.8% stake in the company to Theon International. This transaction, completed in June 2024, marks a significant shift in Exosens’ shareholder structure.

Details of the Transaction

• Exosens is listed on Euronext under the ticker EXENS.
• The sale enables HLD Europe to reduce its holdings and facilitates new investment.
• Theon International, an investment firm focused on technology and healthcare, acquired the stake.

About Exosens and Its Technology

Exosens specializes in developing wearable sensor technology that supports patients with neurological disorders by monitoring motor functions. Their technology aids in managing diseases such as Parkinson’s disease and multiple sclerosis.

Implications of Theon International Investment

1. Funding for further research and development.
2. Acceleration of clinical trials.
3. Expansion into new market areas.

Theon International’s strategic guidance is expected to help Exosens scale its solutions globally, leveraging Theon’s experience in healthcare investments.

Statements from Key Stakeholders

• Exosens CEO expressed optimism about the partnership, emphasizing acceleration in innovation and enhancement of patient care.
• HLD Europe noted satisfaction with Exosens’ progress and confidence that Theon International would bring valuable support.

Compliance and Market Positioning

The share transaction was conducted in accordance with market regulations and Euronext rules, ensuring transparency and timely communication to shareholders and the public.

With rising demand for digital health technologies across Europe, especially for chronic disease management, Exosens is positioned to capitalize on these trends with its advanced sensor products and ongoing clinical collaborations.

Analysts anticipate that Theon International’s fresh capital and expertise will accelerate Exosens’ product launches and support entry into new markets during 2024 and beyond.

About The Author